NasdaqGS - Delayed Quote • USD
uniQure N.V. (QURE)
At close: April 23 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 13 | 13 |
| Avg. Estimate | -1.28 | -1.24 | -4.3 | -3.86 |
| Low Estimate | -1.64 | -1.63 | -5.91 | -6.22 |
| High Estimate | -0.9 | -0.48 | -1.12 | -2.35 |
| Year Ago EPS | -1.63 | -1.44 | -6.47 | -4.3 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 11 | 12 | 13 |
| Avg. Estimate | 6.23M | 5.69M | 50.69M | 84.75M |
| Low Estimate | -- | -- | 7M | 13.4M |
| High Estimate | 19.2M | 19.4M | 167M | 221.2M |
| Year Ago Sales | 28.25M | 207.71M | 15.84M | 50.69M |
| Sales Growth (year/est) | -77.90% | -97.30% | 220.00% | 67.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.95 | 2.05 | -0.85 | -1.45 |
| EPS Actual | -1.63 | -1.44 | -1.88 | -1.53 |
| Difference | -0.68 | -3.49 | -1.03 | -0.08 |
| Surprise % | -71.60% | -170.20% | -121.20% | -5.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.28 | -1.24 | -4.3 | -3.86 |
| 7 Days Ago | -1.28 | -1.24 | -4.3 | -3.86 |
| 30 Days Ago | -1.29 | -1.26 | -4.33 | -3.95 |
| 60 Days Ago | -1.25 | -1.18 | -3.98 | -3.1 |
| 90 Days Ago | -1.25 | -1.18 | -3.98 | -3.1 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | QURE | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 21.50% | -- | -- | 0.40% |
| Next Qtr. | 13.90% | -- | -- | 9.90% |
| Current Year | 33.50% | -- | -- | 4.30% |
| Next Year | 10.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Mizuho: Neutral to Neutral | 3/4/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Downgrade | Goldman Sachs: Buy to Neutral | 2/29/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/19/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 1/16/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 12/20/2023 |
Related Tickers
GOSS Gossamer Bio, Inc.
0.7376
-0.73%
RGNX REGENXBIO Inc.
15.90
+1.66%
FOLD Amicus Therapeutics, Inc.
10.71
-1.02%
IMTX Immatics N.V.
10.42
+2.26%
ETNB 89bio, Inc.
8.92
-4.19%
VYGR Voyager Therapeutics, Inc.
7.65
+1.06%
RARE Ultragenyx Pharmaceutical Inc.
45.11
+3.25%
KROS Keros Therapeutics, Inc.
55.19
-1.06%
PMVP PMV Pharmaceuticals, Inc.
1.8050
+4.34%
PRQR ProQR Therapeutics N.V.
2.0200
+1.00%